Patents

Literature

Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

6645 results about "Pyrrole" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

Pyrrole is a heterocyclic aromatic organic compound, a five-membered ring with the formula C₄H₄NH. It is a colorless volatile liquid that darkens readily upon exposure to air. Substituted derivatives are also called pyrroles, e.g., N-methylpyrrole, C₄H₄NCH₃. Porphobilinogen, a trisubstituted pyrrole, is the biosynthetic precursor to many natural products such as heme.

Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors

ActiveUS20070135461A1Improve actionReduce releaseBiocideAntipyreticDiseaseKinase activity

The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors

Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors

Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors

Owner:INCYTE HLDG & INCYTE

Pyrrolobenzodiazepines as key intermediates in the synthesis of dimeric cytotoxic pyrrolobenzodiazepines

ActiveUS7557099B2BiocideOrganic chemistryCarbamateDouble bond

Compounds and a method of synthesis of compounds of formula (Ia) or (Ib): and salts, solvates, and chemically protected forms thereof, wherein the dotted lines indicate the optional presence of a double bond between C1 and C2 or C2 and C3; R2 and R3 are independently selected from —H, ═O, ═CH2, —CN, —R, OR, halo, ═CH—R, O—SO2—R, CO2R and COR; R10 is a carbamate-based nitrogen protecting group; and R11 is an oxygen protecting group.

Pyrrolobenzodiazepines as key intermediates in the synthesis of dimeric cytotoxic pyrrolobenzodiazepines

Pyrrolobenzodiazepines as key intermediates in the synthesis of dimeric cytotoxic pyrrolobenzodiazepines

Pyrrolobenzodiazepines as key intermediates in the synthesis of dimeric cytotoxic pyrrolobenzodiazepines

Owner:MEDIMMUNE LTD

Pyrrolobenzodiazepines

InactiveUS7528126B2Antibacterial agentsBiocideDouble bondStereochemistry

A compound of formula (I) and salts and solvates thereof, wherein: R10 is a nitrogen protecting group and R11 is either OH or O—R12, wherein R12 is an oxygen protecting group, or R10 and R11 together form a double bond between N10 and C11; and R10′ and R11′ are selected from the same options as R10 and R11 respectively.

Pyrrolobenzodiazepines

Pyrrolobenzodiazepines

Pyrrolobenzodiazepines

Owner:MEDIMMUNE LTD

Non-cross-linking pyrrolo[2,1-c][1,4]benzodiazepines and process thereof

InactiveUS6884799B2BiocideSteroidsBenzodiazineCombinatorial chemistry

The present invention relates to novel pyrrolo[2,1-c][1,4]benzodiazepines compounds of general formula V as shown below, which are useful as potential antitumour agents and a process of preparing these compounds; particularly the present invention provides a process for the preparation of 7-methoxy-8-{n-[7-methoxy-(11aS)-1,2,3,10,11,11a-hexahydro-5H-pyrrolo[2,1-c][1,4]ben-zodiazepine-5-one-8-yloxy]alkyloxy}-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one, with varying aliphatic chain length and its 2-hydroxy derivatives.

Non-cross-linking pyrrolo[2,1-c][1,4]benzodiazepines and process thereof

Non-cross-linking pyrrolo[2,1-c][1,4]benzodiazepines and process thereof

Non-cross-linking pyrrolo[2,1-c][1,4]benzodiazepines and process thereof

Owner:COUNCIL OF SCI & IND RES

Diagnostics based on tetrazolium compounds

InactiveUS6200773B1Bioreactor/fermenter combinationsOrganic chemistryPyrrolo-Quinoline QuinoneDiaphorase

A reagent is suitable for measuring the concentration of an analyte in a hemoglobin-containing biological fluid, such as whole blood. The reagent comprises dehydrogenase enzyme that has specificity for the analyte, NAD, an NAD derivative, pyrrolo-quinoline quinone (PQQ), or a PQQ derivative, a tetrazolium dye precursor, a diaphorase enzyme or an analog thereof, and a nitrite salt. The reagent causes dye formation that is a measure of the analyte concentration. The nitrite salt suppresses interfering dye formation caused non-enzymatically by the hemoglobin. Preferably, the reagent is used in a dry strip for measuring ketone bodies, such as beta-hydroxybutyrate.

Diagnostics based on tetrazolium compounds

Diagnostics based on tetrazolium compounds

Diagnostics based on tetrazolium compounds

Owner:LIFESCAN IP HLDG LLC

11-hydroxy-5h-pyrrolo[2,1-c][1,4] benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines

ActiveUS7741319B2BiocideOrganic chemistryCarbamateLeaving group

The present inventors have developed a key intermediate for the production of C2 substituted PBDs, which has a leaving group at the C2 position, a carbamate protecting group at the N10 position and a protected hydroxy group at the C11 position. In a first aspect, the present invention comprises a compound with a the formula (I), wherein: R10 is a carbamate-based nitrogen protecting group; R11 is an oxygen protecting group; and R2 is a labile leaving group. In a further aspect, the present invention comprises a method of synthesising a compound of formula (III), or a solvate thereof, from a compound of formula (I) as defined in the first aspect, R16 is either O—R11, wherein R11 is as defined in the first aspect, or OH, or R10 and R16 together form a double bond between N10 and C11; and R15 is R. The other substituents are defined in the claims. Further aspects of the present invention relate to compounds of formula (III) (including solvates thereof when R10 and R16 form a double bond between N10 and C11, and pharmaceutical salts thereof), pharmaceutical compositions comprising these, and their use in the manufacture of a medicament for the treatment of a proliferative disease.

11-hydroxy-5h-pyrrolo[2,1-c][1,4] benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines

11-hydroxy-5h-pyrrolo[2,1-c][1,4] benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines

11-hydroxy-5h-pyrrolo[2,1-c][1,4] benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines

Owner:MEDIMMUNE LTD

Glucose sensor

InactiveUS7005048B1Avoid separationImprove reliabilityImmobilised enzymesBioreactor/fermenter combinationsReaction layerElectricity

The present invention provides a high-performance glucose sensor having excellent storage stability and an improved response characteristic. This sensor comprises: an electrically insulating base plate; an electrode system including at least a working electrode and a counter electrode formed on the base plate; and a reaction layer containing at least pyrrolo-quinoline quinone dependent glucose dehydrogenase, formed in contact with or in the vicinity of the electrode system, and the reaction layer contains at least one kind of additive selected from the group consisting of gluconic acid and salts thereof.

Glucose sensor

Glucose sensor

Glucose sensor

Owner:PHC HLDG CORP

Pharmaceutical co-crystal compositions

InactiveUS7927613B2Improve propertiesImprove linearityPowder deliveryBiocidePhosphateKetone

A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.

Pharmaceutical co-crystal compositions

Pharmaceutical co-crystal compositions

Pharmaceutical co-crystal compositions

Owner:JOHNSON & JOHNSON CONSUMER COPANIES +2

HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS

ActiveUS20090181959A1Improve actionReduce releaseBiocideAntipyreticDiseaseKinase activity

The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS

HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS

HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS

Owner:INCYTE HLDG & INCYTE

Stereoselective reduction process for the preparation of pyrrolotriazine compounds

ActiveUS20060286646A1Sugar derivativesHydrolasesAlcoholKetone

The invention relates to a process for the enzymatic, stereoselective reduction of ketone compounds to provide chiral alcohols, for example the compound of formula Ib:

Stereoselective reduction process for the preparation of pyrrolotriazine compounds

Stereoselective reduction process for the preparation of pyrrolotriazine compounds

Stereoselective reduction process for the preparation of pyrrolotriazine compounds

Owner:BRISTOL MYERS SQUIBB CO

Purinone derivative hydrochloride

ActiveUS20140330015A1Good metabolic stabilityImprove solubilityOrganic active ingredientsAntipyreticMast cellSolubility

The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.

Purinone derivative hydrochloride

Purinone derivative hydrochloride

Purinone derivative hydrochloride

Owner:ONO PHARMA CO LTD

Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators

InactiveUS20090005356A1Modulate activityAntibacterial agentsBiocideAutoimmune diseaseAllergy

Provided herein are substituted pyrrolopyridine heterocycles and substituted pyrazolopyridine heterocycles, pharmaceutical compositions comprising said heterocycles and methods of using said heterocycles in the treatment of disease. The heterocycles disclosed herein function as kinase modulators and have utility in the treatment of diseases such as cancer, allergy, asthma, inflammation, obstructive airway disease, autoimmune diseases, metabolic disease, infection, CNS disease, brain tumor, obesity, asthma, hematological disorder, degenerative neural disease, cardiovascular disease, or disease associated with angiogenesis, neovascularization, or vasculogenesis.

Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators

Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators

Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators

Owner:SGX PHARMA INC

1′-substituted carba-nucleoside analogs for antiviral treatment

ActiveUS8008264B2BiocideSaccharide with heterocyclic radicalsPhosphateNucleoside Analogs

Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.

1′-substituted carba-nucleoside analogs for antiviral treatment

1′-substituted carba-nucleoside analogs for antiviral treatment

1′-substituted carba-nucleoside analogs for antiviral treatment

Owner:GILEAD SCI INC

Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-4-yl-amines as janus kinase inhibitors

ActiveUS20060183906A1BiocideNervous disorderPyridineKinase inhibition

The present invention provides pyrrolo[2,3-b]pyridine-4-yl amines pyrrolo[2,3-b]pyrimidin-4-yl amines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer.

Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-4-yl-amines as janus kinase inhibitors

Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-4-yl-amines as janus kinase inhibitors

Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-4-yl-amines as janus kinase inhibitors

Owner:INCYTE HLDG & INCYTE

Pyrrolobenzodiazepines and conjugates thereof

InactiveUS20130028917A1Organic active ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsDiseaseBenzodiazine

Conjugates and compounds for making conjugates which are PBD molecules linked via the N10 position are disclosed, along with the use of the conjugates for treating proliferative diseases, including cancer.

Pyrrolobenzodiazepines and conjugates thereof

Pyrrolobenzodiazepines and conjugates thereof

Pyrrolobenzodiazepines and conjugates thereof

Owner:MEDIMMUNE LTD

Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase

ActiveUS20070054279A1Organic active ingredientsSugar derivativesDouble strandedSingle stranded oligonucleotides

One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one ligand tethered to an altered or non-natural nucleobase. In certain embodiments, the non-natural nucleobase is difluorotolyl, nitropyrrolyl, or nitroimidazolyl. In certain embodiments, the ligand is a steroid or aromatic compound. In certain embodiments, only one of the two oligonucleotide strands comprising the double-stranded oligonucleotide contains a ligand tethered to an altered or non-natural nucleobase. In certain embodiments, both of the oligonucleotide strands comprising the double-stranded oligonucleotide independently contain a ligand tethered to an altered or non-natural nucleobase. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one ligand tethered to an altered or non-natural nucleobase. In certain embodiments, the non-natural nucleobase is difluorotolyl, nitropyrrolyl, or nitroimidazolyl. In certain embodiments, the ligand is a steroid or aromatic compound. In certain embodiments, the ribose sugar moiety that occurs naturally in nucleosides is replaced with a hexose sugar, polycyclic heteroalkyl ring, or cyclohexenyl group. In certain embodiments, at least one phosphate linkage in the oligonucleotide has been replaced with a phosphorothioate linkage.

Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase

Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase

Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase

Owner:ALNYLAM PHARM INC

Pyrrolobenzodiazepines and conjugates thereof

ActiveUS20130266595A1ImmunoglobulinsPharmaceutical non-active ingredientsPyrrolobenzodiazepineMedicinal chemistry

A conjugate of formula (A):

where Y is selected from a single bond, and a group of formulae A1 or A2:

where N shows where the group binds to the N10 of the PBD moiety;

- R^L1and R^L2are independently selected from H and methyl, or together with the carbon atom to which they are bound form a cyclopropylene group;
- CBA represents a cell binding agent;
- Q is independently selected from O, S and NH;
- R¹¹is either H, or R or, where Q is O, SO₃M, where M is a metal cation.

Pyrrolobenzodiazepines and conjugates thereof

Pyrrolobenzodiazepines and conjugates thereof

Pyrrolobenzodiazepines and conjugates thereof

Owner:GENENTECH INC

C2-fluoro pyrrolo [2,1-c][1,4]benzodiazepine dimers

InactiveUS7189710B2BiocideOrganic chemistryBenzodiazepineCombinatorial chemistry

The present invention relates to novel 2-fluoro-pyrrolo[2,1-c][1,4]benzodiazepine dimers useful as antitumour agents and to a process for the preparation thereof.

C2-fluoro pyrrolo [2,1-c][1,4]benzodiazepine dimers

C2-fluoro pyrrolo [2,1-c][1,4]benzodiazepine dimers

C2-fluoro pyrrolo [2,1-c][1,4]benzodiazepine dimers

Owner:COUNCIL OF SCI & IND RES

Pharmaceutical co-crystal compositions

InactiveUS20070026078A1Improve solubilityLow hygroscopicityBiocidePowder deliveryThioketoneHydroxamic acid

A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.

Pharmaceutical co-crystal compositions

Pharmaceutical co-crystal compositions

Pharmaceutical co-crystal compositions

Owner:JOHNSON & JOHNSON CONSUMER COPANIES +2

Pyrrolopyrimidines and related analogs as HSP90-inhibitors

ActiveUS20050107343A1Broad utilityWide range of usesBiocideOrganic active ingredientsDiseaseHsp Inhibitor

Pyrrolopyrimidines and related analogs are described and demonstrated to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents used in the treatment and prevention of various HSP90 mediated disorders, e.g., proliferative disorders. Methods of synthesis and use of such compounds are also described and claimed.

Pyrrolopyrimidines and related analogs as HSP90-inhibitors

Pyrrolopyrimidines and related analogs as HSP90-inhibitors

Pyrrolopyrimidines and related analogs as HSP90-inhibitors

Owner:CONFORMAL THERAPEUTICS CORP (US)

2'-fluoro substituted carba-nucleoside analogs for antiviral treatment

ActiveUS7973013B2Esterified saccharide compoundsSaccharide with heterocyclic radicalsHalogenPhosphate

Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 2′ position of the nucleoside sugar is substituted with halogen and carbon substitutents. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections caused by both wild type and mutant strains of HCV.

2'-fluoro substituted carba-nucleoside analogs for antiviral treatment

2'-fluoro substituted carba-nucleoside analogs for antiviral treatment

2'-fluoro substituted carba-nucleoside analogs for antiviral treatment

Owner:GILEAD SCI INC

Labeling of immobilized proteins using dipyrrometheneboron difluoride dyes

InactiveUS6972326B2Hybrid immunoglobulinsChemiluminescene/bioluminescenceFluorescenceImmobilized protein

The invention describes methods for labeling or detecting of immobilized poly(amino acids), including peptides, polypeptides and proteins, on membranes and other solid supports, using fluorescent dipyrrometheneboron difluoride dyes. Such immobilized poly(amino acids) are labeled or detected on blots or on arrays of poly(amino acids), or are attached to immobilized aptamers.

Labeling of immobilized proteins using dipyrrometheneboron difluoride dyes

Labeling of immobilized proteins using dipyrrometheneboron difluoride dyes

Labeling of immobilized proteins using dipyrrometheneboron difluoride dyes

Owner:MOLECULAR PROBES

Pyrrolobenzodiazepine Therapeutic Agents Useful in the Treatment of Leukemias

InactiveUS20080090812A1BiocideAnimal repellantsArylCarbamate

A pyrrolobenzodiazepine dimer compound of Formula (I): or pharmaceutically acceptable salt or solvate thereof is useful as a therapeutic agent for the treatment of leukaemias, especially B-cell leukaemias, that exhibit resistance to other chemotherapeutic drugs, wherein: the dotted lines indicate the optional presence of a double bond between C1 and C2 or C2 and C3; R²and R³are independently selected from —H, ═O, ═CH₂, —CN, —R, OR, halo, ═CH—R, O—SO₂—R, CO₂R and COR; R⁶, R⁷and R⁹are independently selected from II, R, OII, OR, SII, SR, NII₂, NIIR, NRR′, nitro, Me₃Sn and halo; where R and R′ are independently selected from optionally substituted C_1-12alkyl, C_3-20heterocyclyl and C_5-20aryl groups; R¹⁰is a carbamate-based nitrogen protecting group and R¹⁵is either O—R¹¹, wherein R is an oxygen protecting group, or OH, or R¹⁰and R¹⁵together form a double bond between N10 and C11; R″ is a C_3-12alkylene group, which chain may be interrupted by one or more heteroatoms and/or aromatic rings, and each X is independently selected from 0, S, or NH; R^2′, R^3′, R^6′, R^7′, R^9′, R^10′ and R^15′ are all independently selected from the same lists as previously defined for R², R³, R⁶, R⁷, R⁹, R¹⁰and R¹⁵respectively.

Pyrrolobenzodiazepine Therapeutic Agents Useful in the Treatment of Leukemias

Pyrrolobenzodiazepine Therapeutic Agents Useful in the Treatment of Leukemias

Pyrrolobenzodiazepine Therapeutic Agents Useful in the Treatment of Leukemias

Owner:SPIROGEN

Pyrrolo-pyridine kinase modulatiors

InactiveUS20090143352A1BiocideOrganic chemistryDiseaseKinase activity

The present invention provides novel pyrrolo-pyridine kinase modulators and methods of using the novel pyrrolo-pyridine kinase modulators to treat diseases mediated by kinase activity.

Pyrrolo-pyridine kinase modulatiors

Pyrrolo-pyridine kinase modulatiors

Pyrrolo-pyridine kinase modulatiors

Owner:SGX PHARMA INC

Electrochemical devices incorporating high-conductivity conjugated polymers

InactiveUS6982514B1Light weightReduced operating requirementsPiezoelectric/electrostriction/magnetostriction machinesConductive materialFiberPolymer science

The present invention includes the preparation of highly conducting conjugated polymers and their use as electrochemical actuators, A typical electrochemical actuator comprises a highly conducting, conjugated polymer for the anode or the cathode, or for both the anode and the cathode; suitable conjugate polymers have a conductivity ≧100 S/cm. The material may have any form, including films and fibers. A preferred shape is a strip or a fiber, where the fiber can be solid or hollow, although any shape may be used. Before use, the material may be treated, for example, by immersion in an acid, in order to dope/protonate the material or to introduce anions or to exchange the anion in the polymer for another anion. Other materials may be incorporated in the polyaniline to increase its conductivity or to provide other benefits, such as increased strength. Useful conducting polymers include monomers of anilines, pyrroles, thiophenes, phenylene vinylenes, and derivatives thereof.

Electrochemical devices incorporating high-conductivity conjugated polymers

Electrochemical devices incorporating high-conductivity conjugated polymers

Electrochemical devices incorporating high-conductivity conjugated polymers

Owner:SANTA FE SCI & TECH

Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators

InactiveUS8158647B2Antibacterial agentsBiocideAutoimmune diseaseAllergy

Provided herein are substituted pyrrolopyridine heterocycles and substituted pyrazolopyridine heterocycles, pharmaceutical compositions comprising said heterocycles and methods of using said heterocycles in the treatment of disease. The heterocycles disclosed herein function as kinase modulators and have utility in the treatment of diseases such as cancer, allergy, asthma, inflammation, obstructive airway disease, autoimmune diseases, metabolic disease, infection, CNS disease, brain tumor, obesity, asthma, hematological disorder, degenerative neural disease, cardiovascular disease, or disease associated with angiogenesis, neovascularization, or vasculogenesis.

Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators

Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators

Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators

Owner:SGX PHARMA INC

1'-substituted-carba-nucleoside prodrugs for antiviral treatment

ActiveUS20120020921A1Exposure was also limitedEfficient extractionSaccharide with heterocyclic radicalsBiocidePhosphateSugar

Provided are prodrugs of pyrrolo[1,2-f][1,2,4]triazin-7-yl nucleoside phosphates wherein the 1′ position of the nucleoside sugar is substituted with CN. The compounds, compositions, and methods provided are useful for the treatment Hepatitis C infections.

1'-substituted-carba-nucleoside prodrugs for antiviral treatment

1'-substituted-carba-nucleoside prodrugs for antiviral treatment

1'-substituted-carba-nucleoside prodrugs for antiviral treatment

Owner:GILEAD SCI INC

Pyrrolobenzodiazepines

InactiveUS7244724B2BiocideOrganic chemistryPyrroleMedicinal chemistry

A compound of formula I:or solvate thereof, wherein n is 1 to 10, and M and M′ are independently selected from monovalent pharmaceutically acceptable cations, or together represent a divalent pharmaceutically acceptable cation.

Pyrrolobenzodiazepines

Pyrrolobenzodiazepines

Pyrrolobenzodiazepines

Owner:GOVERNMENT OF THE US REPRESENTED BY THE SEC +1

Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans

InactiveUS20060183758A1Organic active ingredientsBiocideFuranBenzothiophene

Methods of synthesis of intermediates that are useful as bioisosteres of the indole, benzofuran and benzothiophene scaffold are disclosed.

Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans

Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans

Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans

Owner:ADESIS

Pyrrolobenzodiazepines

InactiveUS8501934B2Organic active ingredientsOrganic chemistryPyrroleStereochemistry

Methods of preparing ZC-423 (I) which result in varying enantiomeric ratios.

Pyrrolobenzodiazepines

Pyrrolobenzodiazepines

Pyrrolobenzodiazepines

Owner:MEDIMMUNE LTD

Popular searches

Dermatologic disorders Proliferative disease Molecular biology Carcinosis Janus kinase inhibitor Pyrimidine Protecting group Pharmacology Benzodiazepine Compounds Perylene derivatives

Who we serve

R&D Engineer
R&D Manager
IP Professional

Why Eureka

Industry Leading Data Capabilities
Powerful AI technology
Patent DNA Extraction

Social media

Try Eureka

PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap